Prospect Therapeutics, Inc.'s GCS-100 Exhibits a Low Toxicity Profile in Cancer Patients

* Reuters is not responsible for the content in this press release.

Tue May 19, 2009 2:53pm EDT 

Prospect Therapeutics, Inc.'s GCS-100 Exhibits a Low Toxicity Profile in
Cancer Patients

WELLESLEY HILLS, Mass., May 19 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A.
("Finn"),  announced today that there has been promising initial interest from
pharma companies in the intellectual property of Prospect Therapeutics, Inc.
("Prospect").

GCS-100 has demonstrated single-agent activity in both hematological and solid
tumors, as well as broad-based synergy with multiple approved therapeutics in
an in vitro setting.  Because GCS-100 exhibits a low toxicity profile that
does not overlap with existing treatments, it is easily integrated with
existing therapeutic regimens.

The intellectual property, regulatory dossier, fixed assets and clinical
inventory will be sold at auction on Monday, June 29, 2009 at 12:00 noon.  

Persons interested in bidding must sign a Confidentiality Agreement ("CA")
obtained from Finn's Office -- jffinnjr@earthlink.net or 781-237-8840.  They
will then receive a bid package.

About Prospect Therapeutics, Inc.

Prospect's lead product candidate, GCS-100, is a carbohydrate molecule
designed to inhibit the activity of galectin-3, a protein found in high
concentration in a broad range of human cancers and whose over-expression is
associated with poor prognosis in cancer patients.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke
& Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He
works primarily in the area of management consulting for distressed
enterprises, bankruptcy accounting and related matters, such as assignee for
the benefit of creditors and liquidating agent for a corporation.  He has been
involved in a number of loan workouts and bankruptcy cases for thirty-five
(35) years.  His most recent Assignment for the Benefit of Creditors in the
biotech field was Spherics, Inc. and ActivBiotics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at
781-237-8840 or jffinnjr@earthlink.net or visit the website at
www.finnwarnkegayton.com

SOURCE  Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A., of Finn, Warnke & Gayton, Certified Public
Accountants, +1-781-237-8840, jffinnjr@earthlink.net
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.